Knight Therapeutics Inc. (GUD : TSX)
Common Stock
$10.01
CAD
+0.00 (%)
Last updated: 2026-09-17
Get GUD alerts:
GUD
Knight Therapeutics Inc.
WealthAwesomePerformance
1 Day
+0.50%
1 Week
+1.11%
1 Month
+2.35%
YTD
+69.37%
Key Statistics
Market Cap
$983.30M
52W High
$10.17
52W Low
$5.66
P/E Ratio
66.73
50 Day MA
$9.73
200 Day MA
$7.76
Beta
0.04
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $10.07 | $10.34 | $10.06 | $10.23 | $10.23 | 57,568 |
| 9/16/2026 | $9.99 | $10.15 | $9.86 | $10.01 | $10.01 | 74,353 |
| 9/15/2026 | $9.97 | $10.11 | $9.89 | $9.96 | $9.96 | 45,204 |
| 9/14/2026 | $9.89 | $10.09 | $9.85 | $10.02 | $10.02 | 56,994 |
| 9/11/2026 | $9.75 | $9.86 | $9.74 | $9.85 | $9.85 | 197,470 |
| 9/10/2026 | $9.88 | $9.93 | $9.65 | $9.73 | $9.73 | 82,030 |
| 9/9/2026 | $9.88 | $9.94 | $9.86 | $9.90 | $9.90 | 42,191 |
| 9/8/2026 | $9.90 | $9.94 | $9.80 | $9.90 | $9.90 | 40,304 |
| 9/4/2026 | $9.95 | $10.05 | $9.85 | $10.01 | $10.01 | 44,900 |
| 9/3/2026 | $9.60 | $10.10 | $9.58 | $10.04 | $10.04 | 488,430 |
Analyst Price Targets
Based on analyst covering GUD · as of Sep 17, 2026
Wall Street analysts forecast GUD stock price to rise 11.7% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.19
+11.7% Upside
Current Price
C$10.01
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
30.9%
Annualized
90-Day Vol
27.6%
Annualized
Trend (90d)
+39.6%
Annualized drift
90d Mean
C$11.78
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.72 | C$9.64 – C$11.93 |
| 60 trading days | C$11.24 | C$9.67 – C$13.07 |
| 90 trading days | C$11.78 | C$9.79 – C$14.18 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Knight Therapeutics Inc.
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Financials
- Revenue (TTM)
- $547.31M
- EBITDA
- $81.16M
- Profit Margin
- 2.72%
- ROE (TTM)
- 1.91%
- EPS (Diluted)
- 0.15
- Book Value
- 8.13
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GUD
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| GLO | Global Atomic Corp | $0.71 | +44.90% |
| DIAM | Star Diamond Corp | $0.03 | +25.00% |
| EGLX | Enthusiast Gaming Holdings Inc | $0.04 | +14.29% |
| YRB | Yorbeau Resources Inc | $0.06 | +10.00% |
| COPR | Coppernico Metals Inc. | $0.44 | +8.64% |
| NFGC | New Found Gold Corp. | $2.42 | +7.56% |
| TELY | TelyRx Holdings Inc. | $2.25 | +7.14% |
| LABS | Medipharm Labs Corp | $0.07 | +7.14% |
GUD.TO news timeline
15 articles covering GUD.TO, most recent first
LatestWhat's Going On With Knight Therapeutics Inc. Stock Friday?
August 2026
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock is tanking today
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock fell yesterday
- Why Knight Therapeutics Inc. stock fell yesterday
- Knight Therapeutics Inc. GUD Earnings Miss Estimates by 188.0%
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock is rising today